Selway Asset Management Has $271,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Selway Asset Management lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 85.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,877 shares of the company's stock after selling 10,945 shares during the quarter. Selway Asset Management's holdings in Johnson & Johnson were worth $271,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of JNJ. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at about $4,390,037,000. Raymond James Financial Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth approximately $1,339,878,000. Vanguard Group Inc. grew its position in Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after buying an additional 1,772,706 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after buying an additional 1,729,281 shares in the last quarter. Finally, Amundi lifted its position in shares of Johnson & Johnson by 16.2% during the 4th quarter. Amundi now owns 11,930,183 shares of the company's stock valued at $1,698,984,000 after acquiring an additional 1,660,458 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on JNJ shares. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday. Bank of America lifted their price target on Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research note on Wednesday, March 5th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $171.33.

Remove Ads

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Up 2.9 %

JNJ stock traded up $4.54 during mid-day trading on Thursday, hitting $159.90. The stock had a trading volume of 13,243,050 shares, compared to its average volume of 7,757,538. The stock has a market capitalization of $385.33 billion, a price-to-earnings ratio of 24.04, a PEG ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a fifty day moving average of $159.63 and a 200 day moving average of $156.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the company earned $2.29 earnings per share. The company's revenue was up 5.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.